| Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors Y Jia, CH Yun, E Park, D Ercan, M Manuia, J Juarez, C Xu, K Rhee, ... Nature 534 (7605), 129-132, 2016 | 635 | 2016 |
| CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell ActivationCDK4/6 Inhibition Enhances the Antitumor T-cell Response J Deng, ES Wang, RW Jenkins, S Li, R Dries, K Yates, S Chhabra, ... Cancer discovery 8 (2), 216-233, 2018 | 461 | 2018 |
| Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer JP Robichaux, YY Elamin, Z Tan, BW Carter, S Zhang, S Liu, S Li, T Chen, ... Nature medicine 24 (5), 638-646, 2018 | 347 | 2018 |
| Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity K Vriens, S Christen, S Parik, D Broekaert, K Yoshinaga, A Talebi, ... Nature 566 (7744), 403-406, 2019 | 285 | 2019 |
| LKB1 loss links serine metabolism to DNA methylation and tumorigenesis F Kottakis, BN Nicolay, A Roumane, R Karnik, H Gu, JM Nagle, ... Nature 539 (7629), 390-395, 2016 | 236 | 2016 |
| Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4 X Dai, W Gan, X Li, S Wang, W Zhang, L Huang, S Liu, Q Zhong, J Guo, ... Nature medicine 23 (9), 1063-1071, 2017 | 229 | 2017 |
| Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway KJ Kurppa, Y Liu, C To, T Zhang, M Fan, A Vajdi, EH Knelson, Y Xie, ... Cancer cell 37 (1), 104-122. e12, 2020 | 223 | 2020 |
| PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer B Diskin, S Adam, MF Cassini, G Sanchez, M Liria, B Aykut, C Buttar, E Li, ... Nature immunology 21 (4), 442-454, 2020 | 204 | 2020 |
| Induction of apoptosis in mouse liver by microcystin-LR T Chen, Q Wang, J Cui, W Yang, Q Shi, Z Hua, J Ji, P Shen Molecular & Cellular Proteomics 4 (7), 958-974, 2005 | 179 | 2005 |
| Single and Dual Targeting of Mutant EGFR with an Allosteric InhibitorSingle-agent Allosteric EGFR Inhibitor C To, J Jang, T Chen, E Park, M Mushajiang, DJH De Clercq, M Xu, ... Cancer discovery 9 (7), 926-943, 2019 | 174 | 2019 |
| Profound tissue specificity in proliferation control underlies cancer drivers and aneuploidy patterns LM Sack, T Davoli, MZ Li, Y Li, Q Xu, K Naxerova, EC Wooten, ... Cell 173 (2), 499-514. e23, 2018 | 153 | 2018 |
| RIP1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer W Wang, JM Marinis, AM Beal, S Savadkar, Y Wu, M Khan, PS Taunk, ... Cancer cell 34 (5), 757-774. e7, 2018 | 143 | 2018 |
| CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer H Zhang, CL Christensen, R Dries, MG Oser, J Deng, B Diskin, F Li, Y Pan, ... Cancer cell 37 (1), 37-54. e9, 2020 | 125 | 2020 |
| Chemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer target T Chen, D Ozel, Y Qiao, F Harbinski, L Chen, S Denoyelle, X He, ... Nature Chemical Biology 7 (9), 610-616, 2011 | 121 | 2011 |
| Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity JP Robichaux, YY Elamin, RSK Vijayan, MB Nilsson, L Hu, J He, F Zhang, ... Cancer Cell 36 (4), 444-457. e7, 2019 | 117 | 2019 |
| SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling C Fedele, S Li, KW Teng, CJR Foster, D Peng, H Ran, P Mita, MJ Geer, ... Journal of Experimental Medicine 218 (1), e20201414, 2020 | 110 | 2020 |
| Small-molecule targeting of brachyury transcription factor addiction in chordoma T Sharifnia, MJ Wawer, T Chen, QY Huang, BA Weir, A Sizemore, ... Nature medicine 25 (2), 292-300, 2019 | 109 | 2019 |
| Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with OsimertinibTargeting HER2 with Osimertinib in NSCLC S Liu, S Li, J Hai, X Wang, T Chen, MM Quinn, P Gao, Y Zhang, H Ji, ... Clinical Cancer Research 24 (11), 2594-2604, 2018 | 109 | 2018 |
| In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung AdenocarcinomaAsf1a Regulates Sensitivity to Immune-Checkpoint Therapy F Li, Q Huang, TA Luster, H Hu, H Zhang, WL Ng, A Khodadadi-Jamayran, ... Cancer discovery 10 (2), 270-287, 2020 | 105 | 2020 |
| CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma J Zhou, Z Wu, G Wong, E Pectasides, A Nagaraja, M Stachler, H Zhang, ... Nature communications 8 (1), 13897, 2017 | 94 | 2017 |
Shuai LiNYU Langone Medical CenterVerified email at nyumc.org
